Relative to EpiPen.
Summary
This measure would urge the United States Food and Drug Administration to reconsider its denial of approval for generic alternatives to the epinephrine auto-injector EpiPen, would urge the Congress of the United States to investigate the impact that Mylan NV's monopoly has had on price increases for EpiPen, and would urge the Congress and the President of the United States to take action to limit the unrestrained ability of drug manufacturers to increase prices based on what the market can bear.
Bill status
signed
all 5 stages cleared
Introduction
Aug 2016
Committee Review
Aug 2016
Senate Passage
Aug 2016
Assembly Passage
Aug 2016
Signed into Law
Sep 2016
Introduced Aug 29, 2016
Signed Sep 9, 2016
Floor votes · Senate Aug 31, 2016 · Assembly Aug 31, 2016
How they voted
33–0
Passed
Total votes 33
Aug 31, 2016
D
Democratic23
100% Yea
R
Republican10
100% Yea
Vote distribution
All Yea
All Nay
Mixed
No data
Full legislative history
Actions timeline
Total actions
12
Key actions
3
Committee
3
Sep 9, 2016
Introduced
Enrolled and filed with the Secretary of State at 11 a.m.
legislature
Aug 31, 2016
Senate · Passed
Senate Vote: pass (33-0)
senate
Aug 31, 2016
Lower · Passed
From committee: Be adopted. Ordered to third reading. (Ayes 14. Noes 0.) (August 31).
lower
Aug 31, 2016
Committee
Referred to Com. on HEALTH.
lower
Aug 30, 2016
Upper · Passed
From committee: Ordered to third reading.
upper
Aug 29, 2016
Introduced
Introduced. Referred to Com. on RLS.
upper
1 primary · 2 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Ed Hernandez
DDemocratic
Co
Isadore Hall
DDemocratic
Co
ML
Mark Leno
DDemocratic
Ask Maddy
·
AI policy assistant
Ask Maddy about SJR 29
Scope: CA
Hi! I can help you understand SJR 29. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline